Overview

* Harrow Health Q2 revenue rises 30% yr/yr but misses analyst expectations, per LSEG data

* GAAP net income for Q2 reaches $5.0 mln, adjusted EBITDA at $17.0 mln

* Co secures exclusive U.S. rights to Samsung Bioepis ophthalmology biosimilars

Outlook

* Harrow expects 2025 revenue to exceed $280 mln

* Company anticipates quarterly revenues to surpass $100 mln in 2025

* Harrow projects TRIESENCE to reach $100 mln annual revenue

Result Drivers

* VEVYE GROWTH - VEVYE prescription volumes rose 66% sequentially, contributing to revenue growth, per CEO Mark L. Baum

* VAFA PROGRAM - Strategic alliance with Apollo Care aims to expand VAFA program and boost prescription volumes

* BIOSIMILAR RIGHTS - Exclusive U.S. rights to Samsung Bioepis ophthalmology biosimilars expected to drive future revenue growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $63.70 $66 mln

Revenue mln (8

Analysts

)

Q2 EPS $0.14

Q2 Gross 75.0%

Margin

Q2 Core 80.0%

Gross

Margin

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Harrow Inc ( HROW ) is $60.00, about 42.6% above its August 8 closing price of $34.43

* The stock recently traded at 34 times the next 12-month earnings vs. a P/E of 28 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)